1-Methyltryptophan
1-Methyltryptophan is a chemical compound that is an inhibitor of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase. It is a chiral compound that can exist as both D- and L-isomers.
The L-isomer inhibits IDO weakly but also serves as an enzyme substrate.
The D-isomer does not inhibit IDO at all, but it can inhibit the IDO-related enzyme IDO2 and restore mTOR signaling in cells starved of tryptophan due to IDO activity. D-1MT is also known as indoximod and is currently in clinical trials for cancer treatment, e.g. for advanced melanoma.
A U.S. patent covering salt and prodrug formulations of indoximod was issued to NewLink Genertics on August 15, 2017 providing exclusivity until at least 2036.
